Abstract
Viral-mediated transfer of the herpes simplex virus thymidine kinase (HSV-tk) gene has been demonstrated by several investigators to confer sensitivity to nucleoside analogs such as ganciclovir (GCV) in a variety of tumor cells including brain, prostate, bladder, kidney, ovary, head and neck, lung, pancreas, and liver cancers. Fourteen suicide gene clinical protocols using adenovirus vectors have been conducted, including four in prostate cancer. Two additional protocols for prostate cancer are in preparation in Japan and the Netherlands. A study conducted at Baylor College of Medicine was the first to demonstrate the safety of HSV-tk plus GCV therapy for human prostate cancer and the anticancer activity of gene therapy in this disease. However, it is still in the early stage of its development, with a number of problems to be overcome. Systemic delivery, specific introduction, and specific expression of the target gene are the major issues to be managed in order to establish a clinically relevant treatment strategy.
| Original language | English |
|---|---|
| Pages (from-to) | 67-71 |
| Number of pages | 5 |
| Journal | Molecular Urology |
| Volume | 4 |
| Issue number | 2 |
| Publication status | Published - 2000 |
Fingerprint
ASJC Scopus subject areas
- Urology
Cite this
Suicide gene therapy for urogenital cancer : Current outcome and prospects. / Nasu, Yasutomo; Kusaka, N.; Saika, T.; Tsushima, T.; Kumon, H.
In: Molecular Urology, Vol. 4, No. 2, 2000, p. 67-71.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Suicide gene therapy for urogenital cancer
T2 - Current outcome and prospects
AU - Nasu, Yasutomo
AU - Kusaka, N.
AU - Saika, T.
AU - Tsushima, T.
AU - Kumon, H.
PY - 2000
Y1 - 2000
N2 - Viral-mediated transfer of the herpes simplex virus thymidine kinase (HSV-tk) gene has been demonstrated by several investigators to confer sensitivity to nucleoside analogs such as ganciclovir (GCV) in a variety of tumor cells including brain, prostate, bladder, kidney, ovary, head and neck, lung, pancreas, and liver cancers. Fourteen suicide gene clinical protocols using adenovirus vectors have been conducted, including four in prostate cancer. Two additional protocols for prostate cancer are in preparation in Japan and the Netherlands. A study conducted at Baylor College of Medicine was the first to demonstrate the safety of HSV-tk plus GCV therapy for human prostate cancer and the anticancer activity of gene therapy in this disease. However, it is still in the early stage of its development, with a number of problems to be overcome. Systemic delivery, specific introduction, and specific expression of the target gene are the major issues to be managed in order to establish a clinically relevant treatment strategy.
AB - Viral-mediated transfer of the herpes simplex virus thymidine kinase (HSV-tk) gene has been demonstrated by several investigators to confer sensitivity to nucleoside analogs such as ganciclovir (GCV) in a variety of tumor cells including brain, prostate, bladder, kidney, ovary, head and neck, lung, pancreas, and liver cancers. Fourteen suicide gene clinical protocols using adenovirus vectors have been conducted, including four in prostate cancer. Two additional protocols for prostate cancer are in preparation in Japan and the Netherlands. A study conducted at Baylor College of Medicine was the first to demonstrate the safety of HSV-tk plus GCV therapy for human prostate cancer and the anticancer activity of gene therapy in this disease. However, it is still in the early stage of its development, with a number of problems to be overcome. Systemic delivery, specific introduction, and specific expression of the target gene are the major issues to be managed in order to establish a clinically relevant treatment strategy.
UR - http://www.scopus.com/inward/record.url?scp=0034095809&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034095809&partnerID=8YFLogxK
M3 - Article
C2 - 12006245
AN - SCOPUS:0034095809
VL - 4
SP - 67
EP - 71
JO - Molecular Urology
JF - Molecular Urology
SN - 1091-5362
IS - 2
ER -